Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-130.01	-38.63	-72.7	-135.35	-108.5	-73.96
Depreciation & Amortization	8.34	8.36	8.12	6.22	3.75	2.13
Stock-Based Compensation	19.52	18.87	18.13	16.67	11.66	5.2
Other Adjustments	-2.1	-2.2	-2.95	-3.81	2.76	0.98
Change in Receivables	3.8	-11.43	0.33	1.9	-0.19	-0.7
Changes in Accounts Payable	1.54	-13.71	6.25	5.76	-0.74	6.59
Changes in Accrued Expenses	6.75	7.85	4.18	3.56	1.03	1.11
Changes in Unearned Revenue	87.26	7.52	83.38	50	-	-
Changes in Other Operating Activities	-2.76	0.57	-2.75	11.25	-2.23	-0.71
Operating Cash Flow	-14.68	-22.8	42	-43.8	-92.47	-59.36
Capital Expenditures	-4.98	-4.7	-3.99	-19.04	-12.91	-9.73
Sale of Property, Plant & Equipment	-	-	-	0.06	0.11	0.08
Purchases of Investments	-570.66	-376.68	-230.36	-103.15	-384.42	-
Proceeds from Sale of Investments	313.04	279.54	189.9	210.93	178	-
Investing Cash Flow	-262.6	-101.83	-44.45	88.8	-219.22	-9.65
Issuance of Common Stock	359.33	30.71	99.53	27.61	20.83	237.9
Net Common Stock Issued (Repurchased)	359.33	30.71	99.53	27.61	20.83	237.9
Issuance of Preferred Stock	-	-	-	-	-	143
Net Preferred Stock Issued (Repurchased)	-	-	-	-	-	143
Other Financing Activities	-0.84	-0.36	-0.64	-0.12	-0.36	-3.34
Financing Cash Flow	358.67	30.35	98.89	27.49	20.47	377.56
Net Cash Flow	81.4	-94.28	96.44	72.49	-291.22	308.55
Free Cash Flow	-19.66	-27.5	38.01	-62.84	-105.38	-69.1
FCF Margin	-45.76%	-22.23%	50.26%	-	-	-
Free Cash Flow Per Share	-0.23	-0.33	0.51	-1.22	-2.23	-2.76
Levered Free Cash Flow	-33.87	-32.73	22.5	-77.6	-119.61	-74.57
Unlevered Free Cash Flow	-50.03	-46.82	11.11	-85.92	-123.5	-73.49

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q